126 related articles for article (PubMed ID: 37980853)
1. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
Fakih M; Wang C; Sandhu J; Ye J; Egelston C; Li X
Eur J Cancer; 2024 Jan; 196():113437. PubMed ID: 37980853
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
[TBL] [Abstract][Full Text] [Related]
3. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
[TBL] [Abstract][Full Text] [Related]
5. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S; Tanaka Y; Lin YT; Koyama S; Fukuoka S; Hara H; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Ueno T; Kojima S; Wakabayashi M; Sakamoto N; Kojima M; Kuwata T; Yoshino T; Nishikawa H; Mano H; Endo I; Shitara K; Kawazoe A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38336371
[TBL] [Abstract][Full Text] [Related]
6. Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases.
Margalit O; Lieberman S; Redinsky I; Halparin S; Honig N; Raskin S; Ben-Ayun M; Shacham-Shmueli E; Halpern N; Urban D; Ackerstein A; Shulman K; Ben-Ami E; Semenisty V; Purim O; Yarom N; Golan T; Boursi B; Appel S; Symon Z; Berger R; Mauro D; Krieg AM; Lawrence YR
Clin Colorectal Cancer; 2023 Dec; 22(4):442-449.e1. PubMed ID: 37657954
[TBL] [Abstract][Full Text] [Related]
7. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
9. Does Physical Activity Play a Role in the Efficacy of RegoNivo for MSS-mCRC?
Srikrishna D
Clin Colorectal Cancer; 2022 Jun; 21(2):e76-e77. PubMed ID: 34756679
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study.
Yang K; Han L; Wu S; Qu X; Li Q; Zhao C; Zhou J; Jin X; Wang Y; Yan D; Cheng Z; Hua Y; Zhang Y; Ge Y; Sun J; Deng W; Zhao L; Zhao Y
Cancer Immunol Immunother; 2022 Jun; 71(6):1443-1451. PubMed ID: 34689233
[TBL] [Abstract][Full Text] [Related]
12. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
Elez E; Pericay C; Valladares-Ayerbes M; Bando I; Safont MJ; Gallego J; Grávalos C; Arrivi A; Carrato A; Conde V; Ortiz MJ; López C; Alonso B; Ruiz de Mena I; Díaz-Rubio E; Tabernero J; Aranda E
Br J Cancer; 2019 Aug; 121(5):378-383. PubMed ID: 31363167
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
Ducreux M; Petersen LN; Öhler L; Bergamo F; Metges JP; de Groot JW; Wang JY; García Paredes B; Dochy E; Fiala-Buskies S; Cervantes A; O'Connor JM; Falcone A;
Eur J Cancer; 2019 Dec; 123():146-154. PubMed ID: 31698328
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study.
Nie C; Lv H; Chen B; Xu W; Wang J; Liu Y; Wang S; Zhao J; He Y; Chen X
Front Oncol; 2022; 12():917353. PubMed ID: 36226061
[TBL] [Abstract][Full Text] [Related]
16. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases.
Ye J; Guo W; Wang C; Egelston CA; D'Apuzzo M; Shankar G; Fakih MG; Lee PP
Cancer Res Commun; 2023 Oct; 3(10):2082-2095. PubMed ID: 37768208
[TBL] [Abstract][Full Text] [Related]
18. Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study.
Dai X; Ding W; He Y; Huang S; Liu Y; Wu T
Front Oncol; 2023; 13():1227644. PubMed ID: 37681031
[TBL] [Abstract][Full Text] [Related]
19. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
20. Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials.
Yukami H; Kawazoe A; Lin YT; Koyama S; Fukuoka S; Hara H; Takahashi N; Kojima T; Asayama M; Yoshii T; Bando H; Kotani D; Nakamura Y; Kuboki Y; Mishima S; Wakabayashi M; Kuwata T; Goto M; Higuchi K; Yoshino T; Doi T; Nishikawa H; Shitara K
Clin Cancer Res; 2022 Aug; 28(16):3480-3488. PubMed ID: 35679062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
